Adelene Q. Perkins, Chief Executive Officer at INFINITY PHARMACEUTICALS, INC. (INFI), sold 5,000 shares at $2.78 ($14K) on 2018-03-05, disclosed to the SEC on 2018-03-07.
Scheduled sale ($14k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| INFI | SELL | 2015-06-26 | $55K | — | Filing → |
| INFI | SELL | 2015-05-28 | $128K | — | Filing → |
| INFI | SELL | 2015-05-15 | $122K | — | Filing → |